AbbVie (NYSE:ABBV) Trading 1.2% Higher – What’s Next?

AbbVie Inc. (NYSE:ABBV)’s share price was up 1.2% during mid-day trading on Friday . The company traded as high as $230.47 and last traded at $227.6840. Approximately 6,093,202 shares changed hands during trading, a decline of 11% from the average daily volume of 6,862,657 shares. The stock had previously closed at $224.94.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026’s Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ABBV shares. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Thursday, April 30th. Barclays initiated coverage on AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Morgan Stanley boosted their price objective on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Guggenheim reaffirmed a “buy” rating and issued a $249.00 price objective on shares of AbbVie in a research note on Friday, May 1st. Finally, Royal Bank Of Canada began coverage on AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Stock Performance

The company’s fifty day moving average price is $209.43 and its 200-day moving average price is $219.30. The stock has a market cap of $402.27 billion, a P/E ratio of 112.16, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the prior year, the firm posted $2.46 EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. Analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AbbVie

Several hedge funds and other institutional investors have recently modified their holdings of ABBV. Chelsea Counsel Co. bought a new position in shares of AbbVie in the third quarter worth about $26,000. Litman Gregory Wealth Management LLC bought a new stake in AbbVie during the 4th quarter valued at about $28,000. Imprint Wealth LLC boosted its position in AbbVie by 56.3% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. Westend Capital Management LLC purchased a new stake in AbbVie in the 4th quarter valued at about $29,000. Finally, IFC & Insurance Marketing Inc. bought a new position in AbbVie in the 4th quarter worth about $31,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.